Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Ophthalmology

Understanding Your Scleritis Diagnosis

At a Glance

Scleritis is deep inflammation of the eye’s white outer wall that can cause severe pain and threaten vision. Prompt evaluation by an experienced ophthalmologist, often with a rheumatologist, helps identify related immune conditions and guide treatment with medicines that work throughout the body.

Being diagnosed with scleritis can feel overwhelming, especially when you are dealing with the intense, deep-seated pain that often defines this condition. Because scleritis is rare, you may find that many people—including some healthcare providers—are unfamiliar with it. Understanding the nature of this disease and how it differs from more common eye issues is the first step toward managing it effectively.

What is Scleritis?

Scleritis is a serious medical condition involving inflammation of the sclera, the tough, white outer wall of the eye [1]. Unlike a simple “red eye,” scleritis affects the deep, structural tissues of the eye globe [2].

The pain associated with scleritis is often described as a severe, “boring” ache that can spread to the forehead, jaw, or temple [3]. This pain is a physical signal of the intense inflammation occurring in the dense collagen of your eye [4]. Because the sclera holds the shape of the eye, inflammation here is considered potentially vision-threatening and requires prompt, specialized care [2].

Scleritis vs. Episcleritis

It is common for patients to confuse scleritis with episcleritis, a much more common and generally mild condition.

  • Episcleritis is inflammation of the thin layer of tissue (the episclera) that sits on top of the white of the eye [5]. It usually causes redness and mild discomfort but rarely threatens vision and often clears up on its own [4].
  • Scleritis involves the deeper, thicker layers. It is much more painful and does not resolve without medical treatment [1].

A key difference your doctor looks for is the involvement of deep blood vessels; in scleritis, these vessels do not “blanch” (turn white) when certain eye drops are applied, whereas they do in episcleritis [4].

How Rare is Scleritis?

Scleritis is considered a rare disease. Research indicates that its incidence (the number of new cases diagnosed each year) is between approximately 1.38 and 6.8 cases per 100,000 people [6][7].

Because it is uncommon, your local optometrist or general practitioner may see only a few cases in their entire career. This is why it is often necessary to see a specialist, such as a uveitis specialist or an ophthalmologist with experience in ocular inflammatory diseases, to ensure you receive the correct diagnosis and treatment plan [2].

The Emotional Impact

Receiving a diagnosis for a rare, painful, and potentially sight-threatening condition is a significant life event. It is normal to feel anxious, frustrated, or fearful. Studies have shown that the psychological burden of scleritis is real:

  • Different studies show varying statistics depending on the group measured, with clinical anxiety or depression affecting roughly 9.3% to 21.6% of patients with scleritis [8].
  • A broader review of ocular inflammatory diseases found that up to 35% of patients reported symptoms of anxiety [9].
  • Higher levels of distress are often linked to the severity of the pain and concerns about how the disease might affect your vision or daily life [9][10].

Validating these feelings is a part of your care. Managing the emotional stress is just as important as managing the physical inflammation [11].

Prognosis and Treatment Goals

While scleritis is serious, it is manageable. The primary goal of treatment is to control the inflammation, protect your vision, and relieve your pain [2].

Most patients require systemic therapy—medication that works throughout the whole body—rather than just eye drops [12]. This is because scleritis is often linked to an underlying systemic (body-wide) inflammatory or autoimmune condition, such as rheumatoid arthritis or vasculitis [13]. In fact, about 43% of people with scleritis have an associated immune-mediated disease [13].

Your individualized treatment may involve:

  1. NSAIDs: Strong anti-inflammatory pills for milder cases [2].
  2. Corticosteroids: Often used to quickly bring severe inflammation under control [14].
  3. Immunomodulatory Therapy: If the disease is persistent, “steroid-sparing” medications may be used to keep the immune system in check over the long term [12].
  4. Biologic Therapies: Advanced medications that target specific parts of the immune system for difficult-to-treat cases [15].

With the right care team—often including both an ophthalmologist and a rheumatologist—patients can often achieve disease control (remission) and maintain their vision [16][17].

Helpful Definitions

  • Anterior: The front part of the eye.
  • Posterior: The back part of the eye, behind the visible surface.
  • Necrotizing: Severe inflammation causing tissue thinning or damage.
  • Systemic: Affecting the entire body, not just the eye.
  • Immunosuppressant: A medication that calms an overactive immune system.

Common questions in this guide

What does a scleritis diagnosis mean?
Scleritis means that the deep, tough white outer wall of the eye is inflamed. It often causes severe, deep eye pain and can threaten vision, so prompt evaluation and treatment by an experienced eye specialist are important.
What do anterior, posterior, and necrotizing scleritis mean?
Anterior scleritis affects the front of the eye, while posterior scleritis affects the back behind the visible surface. Necrotizing scleritis describes severe inflammation that causes tissue thinning or damage, and the type and severity help guide monitoring and treatment.
How is scleritis different from episcleritis?
Scleritis affects deeper layers of the eye and is usually much more painful than episcleritis. Episcleritis is often mild and may clear on its own, while scleritis generally needs medical treatment; eye doctors may also use drops to see whether deeper blood vessels turn white.
Could scleritis be related to another health condition?
Yes. Scleritis is often associated with an immune-mediated condition affecting the body, including rheumatoid arthritis or vasculitis. Your clinician may recommend blood tests or imaging to look for an underlying cause and decide whether rheumatology care is needed.
What medicines are used to treat scleritis?
Treatment often uses medicines that work throughout the body rather than eye drops alone. NSAIDs may help milder cases, while corticosteroids can rapidly control severe inflammation; persistent or difficult-to-treat disease may require steroid-sparing immune medicines or biologic therapies.
Who treats scleritis, and can treatment protect my vision?
An ophthalmologist with experience in ocular inflammatory disease, such as a uveitis specialist, can evaluate and treat the eye. A rheumatologist may work with the ophthalmologist when scleritis is linked to a body-wide immune condition or requires long-term immune treatment, with the goal of controlling inflammation and preserving vision.
How might a scleritis diagnosis affect my emotional health?
Severe pain, uncertainty, and fear about vision can contribute to anxiety, low mood, and stress. Sharing these concerns with your care team and using support from family, friends, or mental-health professionals can be part of managing scleritis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What type of scleritis do I have (anterior or posterior), and is it 'necrotizing'?
  2. 2.How much experience do you have treating scleritis, and do you work with a rheumatologist for systemic management?
  3. 3.Given my diagnosis, which specific blood tests or imaging do I need to look for underlying causes?
  4. 4.Since I am in significant pain, what is our immediate plan to manage the inflammation and the pain itself?
  5. 5.What is the goal for my vision, and what signs should I look for that my treatment needs to be adjusted?
  6. 6.How long do you expect I will need to be on systemic medications like steroids or immunosuppressants?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Ocular Pharmacology for Scleritis: Review of Treatment and a Practical Perspective.

    Stem MS, Todorich B, Faia LJ

    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2017; (33(4)):240-246 doi:10.1089/jop.2016.0127.

    PMID: 28355124
  2. 2

    Current Approach for the Diagnosis and Management of Noninfective Scleritis.

    Dutta Majumder P, Agrawal R, McCluskey P, Biswas J

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; (10(2)):212-223 doi:10.1097/APO.0000000000000341.

    PMID: 33290287
  3. 3

    NODULAR POSTERIOR SCLERITIS: Clinico-Sonographic Characteristics and Proposed Diagnostic Criteria.

    Agrawal R, Lavric A, Restori M, et al.

    Retina (Philadelphia, Pa.) 2016; (36(2)):392-401 doi:10.1097/IAE.0000000000000699.

    PMID: 26296144
  4. 4

    Etanercept-associated episcleritis: a pediatric case report of a paradoxical adverse reaction and review of the literature.

    Küçükali B, Gezgin Yıldırım D, Esmeray Şenol P, et al.

    Clinical rheumatology 2024; (43(2)):799-808 doi:10.1007/s10067-023-06793-4.

    PMID: 37845415
  5. 5

    Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era.

    Caimmi C, Crowson CS, Smith WM, et al.

    The Journal of rheumatology 2018; (45(5)):595-603 doi:10.3899/jrheum.170437.

    PMID: 29449499
  6. 6

    The Global Epidemiology of Scleritis: A Systematic Review and Meta-analysis.

    Cifuentes-González C, Mejía-Salgado G, Rojas-Carabali W, et al.

    American journal of ophthalmology 2025; (273()):13-32 doi:10.1016/j.ajo.2025.01.019.

    PMID: 39892801
  7. 7

    Incidence and Prevalence of Scleritis Subtypes and Associated Ocular Complications in the TriNetX Database.

    Spangler MD, Marshall RF, Kirupaharan N, et al.

    American journal of ophthalmology 2025; (277()):365-374 doi:10.1016/j.ajo.2025.05.028.

    PMID: 40447245
  8. 8

    The Association Between Mental Health Disorders and Non-Infectious Scleritis: A Prevalence Study and Review of the Literature.

    Abdel-Aty A, Kombo N

    European journal of ophthalmology 2022; (32(4)):1850-1856 doi:10.1177/11206721211067652.

    PMID: 34913750
  9. 9

    Anxiety and Depression among Patients with Uveitis and Ocular Inflammatory Disease at a Tertiary Center in Southern Thailand: Vision-Related Quality of Life, Sociodemographics, and Clinical Characteristics Associated.

    Sittivarakul W, Wongkot P

    Ocular immunology and inflammation 2019; (27(5)):731-742 doi:10.1080/09273948.2018.1484495.

    PMID: 29969331
  10. 10

    Incidence and Prevalence of Depression, Anxiety, and Suicidal Ideation in Patients with Uveitis and Scleritis in the TriNetX Database.

    Agarwal R, Lee D, Mendez Bermudez I, Berkenstock MK

    Ocular immunology and inflammation 2026; 1-9 doi:10.1080/09273948.2026.2633447.

    PMID: 41824366
  11. 11

    Evaluation and correlation analysis of ocular surface disorders and quality of life in autoimmune rheumatic diseases: a cross-sectional study.

    Ren Y, Tian J, Shi W, et al.

    BMC ophthalmology 2023; (23(1)):229 doi:10.1186/s12886-023-02959-5.

    PMID: 37217899
  12. 12

    Patterns of Non-Infectious Scleritis across a Tertiary Eye Care Network Using the Indigenously Developed Electronic Medical Record System-eyeSmart.

    Murthy SI, Das AV, Kammari P, et al.

    Ocular immunology and inflammation 2022; (30(7-8)):1733-1739 doi:10.1080/09273948.2021.1942497.

    PMID: 34255594
  13. 13

    Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review.

    Morrison T, Gottman M, Do T, et al.

    The Journal of rheumatology 2024; (51(8)):825-830 doi:10.3899/jrheum.2023-0788.

    PMID: 38302174
  14. 14

    Clinical characteristics and efficacy of methotrexate in Japanese patients with noninfectious scleritis.

    Hiyama T, Harada Y, Kiuchi Y

    Japanese journal of ophthalmology 2021; (65(1)):97-106 doi:10.1007/s10384-020-00778-5.

    PMID: 33107015
  15. 15

    Management of noninfectious scleritis.

    Abdel-Aty A, Gupta A, Del Priore L, Kombo N

    Therapeutic advances in ophthalmology 2022; (14()):25158414211070879 doi:10.1177/25158414211070879.

    PMID: 35083421
  16. 16

    Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors.

    Kempen JH, Pistilli M, Begum H, et al.

    American journal of ophthalmology 2021; (223()):377-395 doi:10.1016/j.ajo.2019.03.024.

    PMID: 30951689
  17. 17

    Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study.

    Sharma SM, Damato E, Hinchcliffe AE, et al.

    The British journal of ophthalmology 2021; (105(9)):1256-1262 doi:10.1136/bjophthalmol-2018-312767.

    PMID: 30862619

This page is for informational purposes only and does not constitute medical advice about scleritis. Your ophthalmologist and, when needed, rheumatologist can interpret your symptoms, tests, and treatment plan.

Get notified when new evidence is published on scleritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.